Spin fails to spark for Genesis after $9.6 million loss

Genesis posted a $9.6 million loss, in line with its 2000 float forecast of $9.1 million. It presented a "bright side" by emphasising it had $47.9 million in cash, down from $61 million a year ago.

"All that demonstrates is that they've burned another $13 million of cash without generating any additional revenue," one analyst commented. Revenue fell $8.7 million to $20 million.

CEO Jim Watson said the company had reached agreement with the US Food and Drug Administration on the next phase of trials of its PVAC psoriasis vaccine.

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Anti-spam verification:

Type the text you see in the image into the field below. You are asked to do this in order to verify that this enquiry is not being performed by an automated process.

Related News:

KPG - Kiwi Property Green Bond offer closed
PFI - Capital Change Notice - FY27 LTI Scheme Grant
IKE - 1H FY27 Performance Update
SUM - Summerset Appoints Sue Matthews as Independent Director
GNE - FY27 Q1 Performance Report
FPH - F&P Healthcare statement regarding cyber incident
HGH - Heartland Group confirms leadership endorsements
October 22nd Morning Report
VCT - Operational Performance for the 3 months ended 30 Sept 2026
SKL - Skellerup with strong start, forecasts growth for FY27